DRAFT v8 · Hidden from search engines until launch
News Explained

FDA's April proposal for three GLP-1 ingredients

Planned for · Last updated

SOURCE CHECKNEWS
Event dateAPRIL 30, 2026
Source typeOFFICIAL NOTICE
StatusPROPOSED

On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide and liraglutide from the 503B bulk-substances list used by outsourcing facilities. Official noticeProposed6 FDA said it had not identified a clinical need for those facilities to compound the three drugs from bulk substances. Official noticeProposed6 The original June 29 comment deadline was extended to July 30, 2026; comments have closed, and no final determination was found in the checked agency record. Official noticeProposed69 This proposal concerns one compounding pathway, not every GLP-1 product. Official noticeProposed6

Checked against sources: October 27, 2026 · Editor approval: approved October 27, 2026

Sources

  1. FDA, "FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List," April 30, 2026. Source type: OFFICIAL NOTICE. https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
  2. FDA, "Extension of Comment Period," Federal Register, June 26, 2026. Source type: OFFICIAL NOTICE (July 30 deadline). https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal